Data suggest that more studies are needed to establish if PTX3 has clinical utility for lung cancer diagnosis and management.

Data show that a photodynamic therapy (PDT) dose-dependent upregulation of CRP gene, as well as of PTX3 and ficolin 1 genes in lung tumor A549 cells, and indicate critical role played by PI3K/Akt/AP-1 pathway.

High PTX3 expression is associated with lung cancer.

The aim of this study was to determine the incidence and role of pentraxin-3 (PTX-3) overexpression as a predictive/prognostic marker in small-cell lung carcinoma (SCLC).

Increased expression of PTX3 is correlated with tumor invasion of lung adenocarcinoma.

These results support the potential of serum PTX3 as a lung cancer biomarker in high-risk subjects

these findings suggest that PTX3 is an important mediator of lung cancer progression, and dePTX3 by TM enhances the anticancer effects of Cis. The deglycosylation in chemotherapy may represent a potential novel therapeutic strategy against lung cancer.

Pentraxin 3 (PTX-3) Levels in Bronchoalveolar Lavage Fluid as a lung cancer Biomarker.

Pentraxin 3 acts as a functional effector of Akt/NF-kappaB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.